

May 2, 2023

Perimeter Medical Imaging AI Announces Initiation of Additional Clinical Trial Site at Baptist MD Anderson Cancer Center in Jacksonville, FL

Pivotal clinical trial underway to determine the impact of Perimeter B-Series OCT with ImgAssist AI on positive margin rates during breast conservation surgery

TORONTO and DALLAS, May 2, 2023 /CNW/ - (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) – Perimeter Medical Imaging AI, Inc. ("Perimeter" or the "Company") – a commercial-stage medical technology company – announced the initiation of an additional clinical trial site at Baptist MD Anderson Cancer Center in Jacksonville, FL under the direction of Laila Samiian, MD, FACS.



Laila Samiian, MD, FACS, Director, Breast Program at Baptist MD Anderson Cancer Center, stated, "We are excited to become the newest active site with three investigators anticipated to participate in this clinical study to assess if the Perimeter B-Series with artificial intelligence demonstrates an improvement over the current standard of care. Combining optical coherence tomography with deep learning algorithms could assist us, as surgeons, to better identify regions of interest supporting 'real-time' decisions on margin status in the OR – potentially setting a new standard for specimen imaging technology during breast conservation surgery."

Jeremy Sobotta, Perimeter's Chief Executive Officer stated, "Our ongoing pivotal clinical trial evaluating our breakthrough-device-designated Perimeter B-Series OCT technology with proprietary, next-gen 'ImgAssist' artificial intelligence continues to advance. All initially planned sites have been activated, and we recently received FDA approval to expand the number of institutions to further support patient enrollment. We are excited to initiate Baptist MD Anderson Cancer Center with the goal of further accelerating study completion."

About the Perimeter B-Series OCT with ImgAssist AI Pivotal Trial

Led by Principal Investigator, Dr. Alastair Thompson at the Baylor College of Medicine in Houston, TX, patient enrollment is ongoing in Perimeter's multi-center, randomized two-arm pivotal clinical trial evaluating the investigational Perimeter B-Series OCT combined with its proprietary ImgAssist AI software in approximately 330 patients, with study completion anticipated by the end of 2023.

About Perimeter Medical Imaging AI, Inc.

Based in Toronto, Canada and Dallas, Texas, [Perimeter Medical Imaging AI](#) (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that is currently being evaluated in a pivotal clinical trial, with support from a grant of up to US\$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding the potential benefits of Perimeter S-Series OCT, Perimeter B-Series OCT, and Perimeter ImgAssist; details regarding Perimeter's ongoing clinical trials; and the anticipated completion date of Perimeter's clinical trials, are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Management Discussion and Analysis for the year ended December 31, 2022, which is available on Perimeter's SEDAR profile at www.sedar.com, and could cause actual events or results to

differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws.

📄 View original content to download multimedia <https://www.prnewswire.com/news-releases/perimeter-medical-imaging-ai-announces-initiation-of-additional-clinical-trial-site-at-baptist-md-anderson-cancer-center-in-jacksonville-fl-301813148.html>

SOURCE Perimeter Medical Imaging AI, Inc.